Brief: Innate Pharma Q1 Revenue Up At EUR 26.0 Million

Innate Pharma SA

10/05/2023 06:21

May 10 (Reuters) - Innate Pharma SA  IPH.PA :
    * CASH POSITION OF EUR 135.0 MILLION AS OF MARCH 31, 2023
(NOT
INCLUDING $5 MILLION PAYMENT FROM TAKEDA), ANTICIPATED CASH
RUNWAY INTO MID 2025
    * ANKET® ASSETS IN COLLABORATION WITH SANOFI CONTINUE TO
PROGRESS;
ABSTRACT FOR IPH6101/SAR'579 SELECTED FOR ORAL PRESENTATION AT
ASCO 2023 ANNUAL MEETING
    * EXCLUSIVE WORLDWIDE RIGHTS GRANTED TO TAKEDA TO RESEARCH
AND
DEVELOP ANTIBODY DRUG CONJUGATES (ADC) USING A PANEL OF SELECTED
INNATE ANTIBODIES; INNATE TO RECEIVE $5M UPFRONT PAYMENT AND
ELIGIBLE TO UP TO $410M IN FUTURE MILESTONESPLUS ROYALTIES
    * REVENUES FOR FIRST THREE MONTHS OF 2023 AMOUNTED TO EUR
26.0
MILLION (EUR 2.6 MILLION FOR SAME PERIOD IN 2022)

Source text for Eikon:  ID:nBwbQdMdCa 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))